These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 9436971)

  • 21. Her2/neu analysis in formalin-fixed, paraffin-embedded breast carcinomas: comparison of immunohistochemistry and multiparameter DNA flow cytometry.
    Leers MP; Hoop JG; Nap M
    Anticancer Res; 2003; 23(2A):999-1006. PubMed ID: 12820338
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy.
    Ross JS; Fletcher JA
    Stem Cells; 1998; 16(6):413-28. PubMed ID: 9831867
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differential expression of c-Met, its ligand HGF/SF and HER2/neu in DCIS and adjacent normal breast tissue.
    Lindemann K; Resau J; Nährig J; Kort E; Leeser B; Annecke K; Welk A; Schäfer J; Vande Woude GF; Lengyel E; Harbeck N
    Histopathology; 2007 Jul; 51(1):54-62. PubMed ID: 17593080
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone.
    Mylonas I; Makovitzky J; Jeschke U; Briese V; Friese K; Gerber B
    Anticancer Res; 2005; 25(3A):1719-23. PubMed ID: 16033090
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic utility of fluorescence in situ hybridization for determining HER2 gene amplification in breast cancer.
    Kammori M; Kurabayashi R; Kashio M; Sakamoto A; Yoshimoto M; Amano S; Kaminishi M; Yamada T; Takubo K
    Oncol Rep; 2008 Mar; 19(3):651-6. PubMed ID: 18288397
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quantitative evaluation of HER-2/neu status in breast cancer by fluorescence in situ hybridization and by immunohistochemistry with image analysis.
    Lehr HA; Jacobs TW; Yaziji H; Schnitt SJ; Gown AM
    Am J Clin Pathol; 2001 Jun; 115(6):814-22. PubMed ID: 11392876
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tyrosine kinase activation in breast carcinoma with correlation to HER-2/neu gene amplification and receptor overexpression.
    Bhargava R; Naeem R; Marconi S; Luszcz J; Garb J; Gasparini R; Otis CN
    Hum Pathol; 2001 Dec; 32(12):1344-50. PubMed ID: 11774167
    [TBL] [Abstract][Full Text] [Related]  

  • 28. c-erbB-2 (HER-2/neu) immunohistochemistry in invasive breast cancer: is there concordance between standard sections and tissue microarrays?
    Selvarajan S; Tan SY; Sii LH; Tan PH
    Pathology; 2006 Aug; 38(4):316-20. PubMed ID: 16916720
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HER2/neu amplification in breast cancer: stratification by tumor type and grade.
    Hoff ER; Tubbs RR; Myles JL; Procop GW
    Am J Clin Pathol; 2002 Jun; 117(6):916-21. PubMed ID: 12047143
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genotypic intratumoral heterogeneity in breast carcinoma with HER2/neu amplification: evaluation according to ASCO/CAP criteria.
    Brunelli M; Manfrin E; Martignoni G; Miller K; Remo A; Reghellin D; Bersani S; Gobbo S; Eccher A; Chilosi M; Bonetti F
    Am J Clin Pathol; 2009 May; 131(5):678-82. PubMed ID: 19369627
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HER-2/neu detection in fine-needle aspirates of breast cancer: fluorescence in situ hybridization and immunocytochemical analysis.
    Beatty BG; Bryant R; Wang W; Ashikaga T; Gibson PC; Leiman G; Weaver DL
    Am J Clin Pathol; 2004 Aug; 122(2):246-55. PubMed ID: 15323142
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Amplification and overexpression of HER2/neu gene and HER2/neu protein in salivary duct carcinoma of the parotid gland.
    Cornolti G; Ungari M; Morassi ML; Facchetti F; Rossi E; Lombardi D; Nicolai P
    Arch Otolaryngol Head Neck Surg; 2007 Oct; 133(10):1031-6. PubMed ID: 17938328
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of HER2 gene status in breast cancer by chromogenic in situ hybridization: comparison with immunohistochemistry.
    Kounelis S; Kapranos N; Malamos N; Kouri-Bairaktari E
    Anticancer Res; 2005; 25(2A):939-46. PubMed ID: 15868931
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Amplification of Her-2/neu gene in Her-2/neu-overexpressing and -nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material.
    Xu R; Perle MA; Inghirami G; Chan W; Delgado Y; Feiner H
    Mod Pathol; 2002 Feb; 15(2):116-24. PubMed ID: 11850540
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of the HER-2/neu oncogene by immunohistochemical and fluorescence in situ hybridization analysis in oral and oropharyngeal squamous cell carcinoma.
    Khan AJ; King BL; Smith BD; Smith GL; DiGiovanna MP; Carter D; Haffty BG
    Clin Cancer Res; 2002 Feb; 8(2):540-8. PubMed ID: 11839675
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Activated Akt signaling pathway in invasive ductal carcinoma of the breast: correlation with HER2 overexpression.
    Park SS; Kim SW
    Oncol Rep; 2007 Jul; 18(1):139-43. PubMed ID: 17549359
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of dual immunohistochemistry and chromogenic in situ hybridization for HER2 on a single section.
    Reisenbichler ES; Horton D; Rasco M; Andea A; Hameed O
    Am J Clin Pathol; 2012 Jan; 137(1):102-10. PubMed ID: 22180483
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of ischemic time, fixation time, and fixative type on HER2/neu immunohistochemical and fluorescence in situ hybridization results in breast cancer.
    Moatamed NA; Nanjangud G; Pucci R; Lowe A; Shintaku IP; Shapourifar-Tehrani S; Rao N; Lu DY; Apple SK
    Am J Clin Pathol; 2011 Nov; 136(5):754-61. PubMed ID: 22031314
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Protein overexpression and gene amplification of c-erbB-2 in breast carcinomas: a comparative study of immunohistochemistry and fluorescence in situ hybridization of formalin-fixed, paraffin-embedded tissues.
    Kobayashi M; Ooi A; Oda Y; Nakanishi I
    Hum Pathol; 2002 Jan; 33(1):21-8. PubMed ID: 11823970
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fixation time and HER2/neu assessment.
    Bohn OL; Sanchez-Sosa S; Ibarra JA; Rogers LW
    Am J Clin Pathol; 2011 Jun; 135(6):979-80; author reply 980. PubMed ID: 21571969
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.